1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Vanamee, É. S. & Faustman, D. L. Structural principles of tumor necrosis
factor superfamily signaling. Sci. Signal. 11, eaao4910 (2018).
Vanamee, E. S. & Faustman, D. L. On the TRAIL of better therapies:
understanding TNFRSF structure-function. Cells 9, 764 (2020).
Wajant, H. Principles of antibody-mediated TNF receptor activation. Cell
Death Differ. 22, 1727–1741 (2015).
Mukai, Y. et al. Solution of the structure of the TNF-TNFR2 complex. Sci.
Signal. 3, ra83–ra83 (2010).
Wang, J. et al. TNFR2 ligation in human T regulatory cells enhances IL2induced cell proliferation through the non-canonical NF-κB pathway. Sci. Rep.
8, 12079 (2018).
Ward-Kavanagh, L. K., Lin, W. W., Šedý, J. R. & Ware, C. F. The TNF
receptor superfamily in co-stimulating and co-inhibitory responses. Immunity
44, 1005–1019 (2016).
Chen, X. & Oppenheim, J. J. The phenotypic and functional consequences of
tumour necrosis factor receptor type 2 expression on CD4+ FoxP3+
regulatory T cells. Immunology 133, 426–433 (2011).
Chen, X. et al. TNFR2 is critical for the stabilization of the CD4+Foxp3+
regulatory T cell phenotype in the inflammatory environment. J. Immunol.
190, 1076–1084 (2013).
Bai, J., Ding, B. & Li, H. Targeting TNFR2 in cancer: all roads lead to Rome.
Front. Immunol. 13, 844931 (2022).
Medler, J., Kucka, K. & Wajant, H. Tumor necrosis factor Receptor 2
(TNFR2): an emerging target in cancer therapy. Cancers 14, https://doi.org/10.
3390/cancers14112603 (2022).
Torrey, H. et al. Targeting TNFR2 with antagonistic antibodies inhibits
proliferation of ovarian cancer cells and tumor-associated Tregs. Sci. Signal.
10, eaaf8608 (2017).
Yang, M. et al. Optimizing TNFR2 antagonism for immunotherapy with
tumor microenvironment specificity. J. Leukoc. Biol. 107, 971–980
(2020).
Chen, Y., Jia, M., Wang, S., Xu, S. & He, N. Antagonistic antibody targeting
TNFR2 inhibits regulatory T cell function to promote anti-tumor activity.
Front. Immunol. 13, 835690 (2022).
Faustman, D. & Davis, M. TNF receptor 2 pathway: drug target for
autoimmune diseases. Nat. Rev. Drug Discov. 9, 482–493 (2010).
Inoue, M. et al. Characterization of a TNFR2-selective agonistic TNF-α
mutant and its derivatives as an optimal regulatory T cell expander. J.
Immunol. 206, 1740–1751 (2021).
Okubo, Y., Torrey, H., Butterworth, J., Zheng, H. & Faustman, D. L. Treg
activation defect in type 1 diabetes: correction with TNFR2 agonism. Clin.
Transl. Immunol. 5, e56 (2016).
Carter, P. J. & Lazar, G. A. Next generation antibody drugs: pursuit of the
‘high-hanging fruit’. Nat. Rev. Drug Discov. 17, 197–223 (2018).
ARTICLE
18. Fischer, R., Kontermann, R. E. & Pfizenmaier, K. Selective targeting of TNF
receptors as a novel therapeutic approach. Front. Cell Dev. Biol. 8, 401 (2020).
19. Richter, F. et al. Monovalent TNF receptor 1-selective antibody with improved
affinity and neutralizing activity. MAbs 11, 166–177 (2019).
20. Akiba, H. & Tsumoto, K. Development and activities, including
immunocomplex formation, of biparatopic antibodies and alternative scaffold
proteins. Transl. Regul. Sci. 2, 1–6 (2020).
21. Oostindie, S. C., Lazar, G. A., Schuurman, J. & Parren, P. W. H. I. Avidity in
antibody effector functions and biotherapeutic drug design. Nat. Rev. Drug
Discov. 21, 715–735 (2022).
22. Kondo, H. et al. Method for creating same and utilization thereof. Patent
application publication. WO/2018/092907 (2018).
23. Yu, X. et al. Reducing affinity as a strategy to boost immunomodulatory
antibody agonism. Nature 614, 539–547 (2023).
24. Kast, F. et al. Engineering an anti-HER2 biparatopic antibody with a
multimodal mechanism of action. Nat. Commun. 12, 3790 (2021).
25. Yang, Y. et al. Tetravalent biepitopic targeting enables intrinsic antibody
agonism of tumor necrosis factor receptor superfamily members. MAbs 11,
996–1011 (2019).
26. Li, J. Y. et al. A biparatopic HER2-targeting antibody-drug conjugate induces
tumor regression in primary models refractory to or ineligible for HER2targeted therapy. Cancer Cell 29, 117–129 (2016).
27. Andres, F. et al. Inhibition of the MET kinase activity and cell growth in METaddicted cancer cells by bi-paratopic linking. J. Mol. Biol. 431, 2020–2039
(2019).
28. Stefano, J. E. et al. A highly potent CD73 biparatopic antibody blocks
organization of the enzyme active site through dual mechanisms. J. Biol.
Chem. 295, 18379–18389 (2020).
29. Merchant, M. et al. Monovalent antibody design and mechanism of action of
Onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic
agent. Proc. Natl Acad. Sci. USA 110, E2987–E2996 (2013).
30. Richter, F. et al. Antagonistic TNF receptor one-specific antibody
(ATROSAB): receptor binding and in vitro bioactivity. PLOS ONE 8, e72156
(2013).
31. Richter, F., Seifert, O., Herrmann, A., Pfizenmaier, K. & Kontermann, R. E.
Improved monovalent TNF receptor 1-selective inhibitor with novel
heterodimerizing Fc. MAbs 11, 653–665 (2019).
32. De Gasparo, R. et al. Bispecific IgG neutralizes SARS-CoV-2 variants and
prevents escape in mice. Nature 593, 424–428 (2021).
33. Galimidi, R. P. et al. Intra-spike crosslinking overcomes antibody evasion by
HIV-1. Cell 160, 433–446 (2015).
34. Croft, M., Benedict, C. A. & Ware, C. F. Clinical targeting of the TNF and
TNFR superfamilies. Nat. Rev. Drug Discov. 12, 147–168 (2013).
35. Jost, C. et al. Structural basis for eliciting a cytotoxic effect in HER2overexpressing cancer cells via binding to the extracellular domain of HER2.
Structure 21, 1979–1991 (2013).
36. Tamaskovic, R. et al. Intermolecular biparatopic trapping of ErbB2 prevents
compensatory activation of PI3K/AKT via RAS-p110 crosstalk. Nat. Commun.
7, 11672 (2016).
37. DaSilva, J. O. et al. A biparatopic antibody that modulates MET trafficking
exhibits enhanced efficacy compared with parental antibodies in MET-driven
tumor models. Clin. Cancer Res. 26, 1408–1419 (2020).
38. Akiba, H. et al. Production of IgG1-based bispecific antibody without extra
cysteine residue via intein-mediated protein trans-splicing. Sci. Rep. 11, 19411
(2021).
39. Onda, M. et al. Characterization of the B cell epitopes associated with a
truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins
for the treatment of cancer patients. J. Immunol. 177, 8822–8834 (2006).
40. Nagata, S. et al. Rapid grouping of monoclonal antibodies based on their
topographical epitopes by a label-free competitive immunoassay. J. Immunol.
Methods 292, 141–155 (2004).
41. Akiba, H., Satoh, R., Nagata, S. & Tsumoto, K. Effect of allotypic variation of
human IgG1 on the thermal stability of disulfide-linked knobs-into-holes
mutants of the Fc for stable bispecific antibody design. Antib. Ther. 2, 65–69
(2019).
42. Akiba, H., Tamura, H., Caaveiro, J. M. M. & Tsumoto, K. Computer-guided
library generation applied to the optimization of single-domain antibodies.
Protein Eng. Des. Sel. 32, 423–431 (2019).
43. Young, G. et al. Quantitative mass imaging of single biological
macromolecules. Science 360, 423–427 (2018).
44. Kimanius, D., Dong, L., Sharov, G., Nakane, T. & Scheres, S. H. W. New tools
for automated cryo-EM single-particle analysis in RELION-4.0. Biochem. J.
478, 4169–4185 (2021).
45. Mastronarde, D. N. Automated electron microscope tomography using robust
prediction of specimen movements. J. Struct. Biol. 152, 36–51 (2005).
46. Yonekura, K., Maki-Yonekura, S., Naitow, H., Hamaguchi, T. & Takaba, K.
Machine learning-based real-time object locator/evaluator for cryo-EM data
collection. Commun. Biol. 4, 1044 (2021).
COMMUNICATIONS BIOLOGY | (2023)6:987 | https://doi.org/10.1038/s42003-023-05326-8 | www.nature.com/commsbio
11
ARTICLE
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-023-05326-8
47. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC:
algorithms for rapid unsupervised cryo-EM structure determination. Nat.
Methods 14, 290–296 (2017).
48. Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive
regularization improves single-particle cryo-EM reconstruction. Nat. Methods
17, 1214–1221 (2020).
49. Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein
structures and complexes. Nucleic Acids Res 46, W296–W303 (2018).
50. Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory
research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
51. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development
of coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
52. Adams, P. D. et al. Phenix: a comprehensive Python-based system for
macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66,
213–221 (2010).
53. Linderman, G. C., Rachh, M., Hoskins, J. G., Steinerberger, S. & Kluger, Y.
Fast interpolation-based t-SNE for improved visualization of single-cell RNAseq data. Nat. Methods 16, 243–245 (2019).
H.A., S.N., and K.T. filed a patent related to the described biparatopic antibodies
(WO2021200840). H.K. and S.N. are co-founders of Epitope Science Co., Ltd. The other
authors have no conflicts of interest to declare.
Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s42003-023-05326-8.
Correspondence and requests for materials should be addressed to Hiroki Akiba, Satoshi
Nagata or Kouhei Tsumoto.
Peer review information Communications Biology thanks the anonymous reviewers for
their contribution to the peer review of this work. Primary Handling Editor: Gene
Chong.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Acknowledgements
The authors thank Reiko Satoh and Mayumi Niiyama for their technical assistance with
protein production, Dr. Yasuhiro Abe, Akiko Abe, Takahide Mori, Miho Mukai, and
Sayuri Okamoto for their assistance with the production of antibody panels, and Dr.
Kohei Shiba for assistance with mass photometry. This study was supported partially by
Japan Agency for Medical Research and Development (AMED) grant numbers
JP22ak0101099 (H.A. and H.K.), JP21am0101117 (K.Na.), JP22ama121003 (K.Na.),
JP17pc0101020 (K.Na.), Japan Science and Technology Agency (JST) grant number
JPMJOP1861 (KNa), Japan Society for the Promotion of Science (JSPS) grant numbers
JP21K06453 (H.A.), JP20K22630 (J.F.), Kyoto University Foundation (H.A.), Takeda
Science Foundation (H.A.), and JEOL YOKOGUSHI Research Alliance Laboratory of
Osaka University (K.Na.).
Author contributions
Conceptualization: H.A., H.K., S.N., K.T.; Investigation: H.A., T.I., J.F., K.Ni., T.M., T.K.,
S.N.; Funding acquisition: H.A., J.F., K.Na., H.K.; Writing—original draft: H.A., J.F., S.N.;
Writing—review and editing: T.K., K.Na., H.O., H.K., K.T.
12
Competing interests
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons licence, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2023
COMMUNICATIONS BIOLOGY | (2023)6:987 | https://doi.org/10.1038/s42003-023-05326-8 | www.nature.com/commsbio
...
論文の公開元へ
